Minkyu represents investment banks and public and private companies, particularly in the life sciences and technology industries, on capital markets and general corporate matters. He provides advice on a variety of securities transactions, including initial public offerings, follow-on equity offerings, PIPE financings and Rule 144A transactions.
Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).
Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.
Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.
NewAmsterdam Pharma – $181.6 Million Follow-on Offering
June 6, 2023
Cooley advised the underwriters in NewAmsterdam Pharma’s $181.6 million follow-on offering. NewAmsterdam is a clinical-stage biopharmaceutical company with a mission to improve care of patients with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. Lawyers Eric Blanchard, Div Gupta, Jean Park, Minkyu Park, Charles York, and Katie Lapidus led the Cooley team.
Olink Holding AB – $116.6 Million Follow-on Offering
January 18, 2023
Cooley advised the underwriters in Olink Holding AB’s $116.6 million follow-on offering. Olink is a company dedicated to working with the scientific community on accelerating proteomics across multiple disease areas to enable new discoveries and improve the lives of patients. Lawyers Eric Blanchard, Charlie Kim, Minkyu Park, Ryan Walker, Katie Lapidus, Megan Taing and Charles York led the Cooley team.
